About Tarsus Rx
Tarsus Rx is a company based in Irvine (United States) founded in 2017 was acquired by Portage Biotech in July 2022.. Tarsus Rx has raised $60 million across 1 funding round from investors including Frazier Healthcare Partners, Portage Biotech and Vivo Capital. The company has 323 employees as of December 31, 2024. Tarsus Rx offers products and services including XDEMVY, TP-04, and TP-05. Tarsus Rx operates in a competitive market with competitors including Aperta Biosciences, among others.
- Headquarter Irvine, United States
- Employees 323 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tarsus Pharmaceuticals, Inc.
-
Annual Revenue
$182.95 M948.62as on Dec 31, 2024
-
Net Profit
$-115.55 M14.97as on Dec 31, 2024
-
EBITDA
$-119.34 M16.12as on Dec 31, 2024
-
Total Equity Funding
$60 M (USD)
in 1 rounds
-
Latest Funding Round
$60 M (USD), Series B
Jan 08, 2020
-
Investors
Frazier Healthcare Partners
& 6 more
-
Employee Count
323
as on Dec 31, 2024
-
Acquired by
Portage Biotech
(Jul 07, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tarsus Rx
Tarsus Rx is a publicly listed company on the NASDAQ with ticker symbol TARS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Tarsus Rx
Tarsus Rx offers a comprehensive portfolio of products and services, including XDEMVY, TP-04, and TP-05. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
FDA-approved treatment for Demodex blepharitis eye condition
Potential treatment for ocular rosacea inflammatory condition
Investigational option for preventing Lyme disease transmission
Unlock access to complete
Software Development Team
56 people
Leadership Team
33 people
Sales and Marketing
14 people
Legal and Compliance
9 people
Human Resources and Administration
7 people
Finance and Accounting
6 people
Sr. Team
3 people
Manager Team
3 people
Unlock access to complete
Funding Insights of Tarsus Rx
Tarsus Rx has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series B round of $60 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $60.0M
-
First Round
First Round
(08 Jan 2020)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Series B - Tarsus Rx | Valuation | Vivo Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tarsus Rx
Tarsus Rx has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Frazier Healthcare Partners, Portage Biotech and Vivo Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tarsus Rx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tarsus Rx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tarsus Rx Comparisons
Competitors of Tarsus Rx
Tarsus Rx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aperta Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Develops innovative treatments for blepharitis and ocular surface diseases through biopharma research.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tarsus Rx
Frequently Asked Questions about Tarsus Rx
When was Tarsus Rx founded?
Tarsus Rx was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Where is Tarsus Rx located?
Tarsus Rx is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Who is the current CEO of Tarsus Rx?
Bobak Azamian is the current CEO of Tarsus Rx.
Is Tarsus Rx a funded company?
Tarsus Rx is a funded company, having raised a total of $60M across 1 funding round to date. The company's 1st funding round was a Series B of $60M, raised on Jan 08, 2020.
How many employees does Tarsus Rx have?
As of Dec 31, 2024, the latest employee count at Tarsus Rx is 323.
What is the annual revenue of Tarsus Rx?
Annual revenue of Tarsus Rx is $182.95M as on Dec 31, 2024.
What does Tarsus Rx do?
Tarsus was founded in 2017 and is headquartered in Irvine, United States. Focus is placed on the pharmaceutical sector, specifically ophthalmology, where proprietary drugs for eye conditions are developed. The lead candidate, TP-03, a topical ophthalmic treatment for Demodex blepharitis, is advancing through Phase 2b3 clinical trials. Additional pipeline efforts target other ocular disorders, with operations centered on drug innovation and testing.
Who are the top competitors of Tarsus Rx?
Tarsus Rx's top competitors include Aperta Biosciences.
What products or services does Tarsus Rx offer?
Tarsus Rx offers XDEMVY, TP-04, and TP-05.
Is Tarsus Rx publicly traded?
Yes, Tarsus Rx is publicly traded on NASDAQ under the ticker symbol TARS.
Who are Tarsus Rx's investors?
Tarsus Rx has 7 investors. Key investors include Frazier Healthcare Partners, Portage Biotech, Vivo Capital, Flying L Partners, and Visionary Ventures.
What is Tarsus Rx's ticker symbol?
The ticker symbol of Tarsus Rx is TARS on NASDAQ.